The content of adiponectin, resistin in serum and their ratio in patients with chronic heart failure in overweight and obesity depending on severity of disease, body mass index, age, gender and myocardium contractile ability

Authors

  • P. P. Bidzilya Zaporizhzhia State Medical University,

DOI:

https://doi.org/10.14739/2310-1210.2017.3.100568

Keywords:

heart failure, adiponectin, resistin, overweight, obesity

Abstract

Recently more and more attention of researchers is paid to determining of adiponectin and resistin role in the development, progression and outcomes of chronic heart failure (CHF) with overweight and obesity, given the continuing increase in the incidence of both pathologies.

Purpose – to examine the contents of adiponectin and resistin in serum and their ratio in patients with CHF in overweight and obesity depending on severity of disease, body mass index, age, gender and contractile myocardial ability.

Materials and Methods. We examined 100 patients of the main group who had CHF of II–III functional class (FC) on the background of normal, overweight and obesity I–III degree. The comparison group included 12 patients with cardiac pathology and normal weight without clinical and instrumental signs of CHF, matched by age and gender. The control group consisted of 12 healthy subjects with normal weight. The presence of normal, overweight and degree of obesity was calculated based on the body mass index (BMI). The level of adiponectin and resistin in the blood serum was determined with ELISA method.

Results. In patients with CHF, overweight and obesity the content of adiponectin and resistin in serum is increased and depends on FC of disease and age. Increasing degree of overweight and reducing the myocardium contractile ability are characterized by higher levels of resistin. The resistin/adiponectin ratio in patients with CHF, overweight and obesity increases with increasing BMI, in relation to the adiponectin/resistin ratio opposite changes occur.

Conclusions. In CHF patients with concomitant overweight and obesity is an excessive activation of adipocytokines system, which is manifested by increase in the content of adiponectin, resistin, resistin/adiponectin ratio and a reduction of adiponectin/resistin index.

 

References

Marques, M. B., & Langouche, L. (2013). Endocrine, metabolic, and morphologic alterations of adipose tissue during critical illness. Crit. Care Med., 41(1), 317–325. doi: 10.1097/CCM.0b013e318265f21c.

Wojciechowska, C., Jacheć, W., Romuk, E., Nowalany-Kozielska, E., Tomasik, A., & Siemińska, L. (2017). The effect of BMI, serum leptin, and adiponectin levels on prognosis in patients with non-ischaemic dilated cardiomyopathy. Endokrynol. Pol., 68(1), 26–34. doi: 10.5603/EP.2017.0005.

Voronkov, L. G., Gavrilenko, T. I., Ilnytska, M. R., Yakushko, L. V., & Rizhkova, N. O. (2016). Kharakterystyka imunopatolohichnykh reaktsii u patsiientiv iz khronichnoiu sertsevoiu nedostatnistiu zalezhno vid naiavnosti insulinorezystentnosti [Parameter immunopathological reactions in patients with chronic heart failure depend on insulin resistance]. Ukrainskyi revmatolohichnyi zhurnal, 4(66), 35–40.

Ntaios, G., Gatselis, N. K., Makaritsis, K., & Dalekos, G. N. (2013). Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis, 227(2), 216–221. doi: 10.1016/j.atherosclerosis.2012.12.029.

Djousse, L., Wilk, J. B., Hanson, N. Q., Glynn, R. J., Tsai, M. Y., & Gaziano, J. M. (2013). Association between adiponectin and heart failure risk in the physicians’ health study. Obesity (Silver Spring), 21, 831–834. doi: 10.1002/oby.20260.

Sente, T., Van Berendoncks, A. M., Hoymans, V. Y., & Vrints, C. J. (2016). Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. Journal of Cachexia, Sarcopenia and Muscle, 7: 261–274. doi: 10.1002/jcsm.12086.

Özcan, K. S., Güngör, B., Altay, S., Osmonov, D., Ekmekçi, A., Özpamuk, F., et al. (2014). Increased level of resistin predicts development of atrial fibrillation. J. Cardiol., 63(4), 308–312. doi: 10.1016/j.jjcc.2013.10.008.

Park, K. H., & Ahima, R. S. (2013). Resistin in Rodents and Humans. Diabetes Metab. J., 37, 404–414. doi: 10.4093/dmj.2013.37.6.404.

Voronkov, L. G., Amosova, K. M., Bahrii, A. E., Dziak, H. V., Diadyk, O. I., Zharinov, O. Y., et al. (2013). Rekomendatsii z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti Asotsiatsii kardiolohiv Ukrainy ta Ukrainskoi asotsiatsii fakhivtsiv iz sertsevoi nedostatnosti [Guidelines for the diagnosis and treatment of chronic heart failure Association of cardiologists of Ukraine and the Ukrainian Association of specialists in heart failure]. Ukrainiskyi kardiolohichnyi zhurnal, 1(Add), 6–44. [in Ukrainian].

Rubio-Guerra, A. F., Cabrera-Miranda, L. J., Vargas-Robles, H., Maceda-Serrano, A., Lozano-Nuevo, J. J., & Escalante-Acosta, B. A. (2013). Correlation between levels of circulating adipokines and adiponectin/resistin index with carotid intima-media thickness in hypertensive type 2 diabetic patients. Cardiology, 125 (3): 150–153. doi: 10.1159/000348651.

Szabo T., Scherbakov, N., Sandek, A., Kung, T., von Haehling, S., Lainscak, M., et al. (2014). Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis. Nutrition, Metabolism & Cardiovascular Diseases, 24, 50–56. doi: 10.1016/j.numecd.2013.04.015.

Cherneva, R. V., Georgiev, O. B., Petrova, D. S., Manov, E. I., & Petrova, J. I. (2014). Resistin and Cardiac Remodeling in Patients with Obstructive Sleep Apnea. J. Pulm. Respir. Med., 4, 3.

Hameed, I. K., Rashid, N. F., & Abed, B. A. (2013). Homestasis Model Assessment–Adiponectin ratio and Adiponectin –Resistin index as markers of insulin resistance in type 2 diabetes mellitus. J. Fac. Med. Baghdad., 55(2), 175–178.

Menzaghi, C., Bacci, S., Salvemini, L., Mendonca, C., Palladino, G., Fontana, A., et al. (2013). Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 Diabetes. PLOS ONE, 6(3), e64729. doi: 10.1371/journal.pone.0064729.

Takeishi, Y. (2013). Resistin Is a Novel Biomarker for a Risk of Heart Failure Resistin Is a Novel Biomarker for a Risk of Heart Failure. J. Cardiovasc. Dis. Diagn., 1(4), 122. doi: 10.4172/2329-9517.1000122.

Downloads

How to Cite

1.
Bidzilya PP. The content of adiponectin, resistin in serum and their ratio in patients with chronic heart failure in overweight and obesity depending on severity of disease, body mass index, age, gender and myocardium contractile ability. Zaporozhye Medical Journal [Internet]. 2017May5 [cited 2024Nov.24];(3). Available from: http://zmj.zsmu.edu.ua/article/view/100568

Issue

No. 3 (2017)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)